{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:18:44Z","timestamp":1788034724415,"version":"build-2784847793"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax\/azacitidine\/low\u2010dose cytarabine\/aclarubicin\/granulocyte colony\u2010stimulating factor (G\u2010CSF) (VA\u2010CAG) in young patients with newly diagnosed acute myeloid leukemia (ND\u2010AML). The VA\u2010CAG regimen included venetoclax (100\u2009mg\/day, Days 1\u20132; 200\u2009mg, Day 3; 400\u2009mg\/day, Days 4\u201321), azacitidine (75\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , Days 1\u20137), cytarabine (10\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    \/12\u2009h, Days 1\u20137), aclarubicin (12\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , Days 1, 3, 5, and 7), and G\u2010CSF (5\u2009\u03bcg\/kg\/day, Days 0\u20138). The primary endpoint was the complete remission (CR) rate after Cycle 1; the secondary endpoints included measurable residual disease (MRD)\u2010negative remission rate, adverse events, and duration of remission (DOR). A total of 120 subjects were enrolled. The median age was 50 years (interquartile range, IQR, 36\u201357). The CR and composite complete response (CRc) rates were 91% (95% CI 86%\u201396%) and 95% (95% CI 91%\u201399%), respectively; 84% (95% CI 81%\u201388%) of the CRc patients achieved MRD\u2010negative remission. Common Grade \u22654 adverse events included neutropenia (96%), thrombocytopenia (86%), febrile neutropenia (24%), pneumonia (4%), and sepsis (4%). The median times to recovery of absolute neutrophil count (ANC)\u2009\u2265\u20090.5 \u00d7 10\n                    <jats:sup>9<\/jats:sup>\n                    \/L and platelet count \u2265 20 \u00d7 10\n                    <jats:sup>9<\/jats:sup>\n                    \/L for responding patients were 14 days (IQR, 9\u201319) and 10 days (IQR, 4\u201316), and the 60\u2010day mortality rate was 0%. With a median follow\u2010up of 22.1 months (95% CI 20.4\u201323.7 months), 34 subjects subsequently received hematopoietic stem cell transplantation (HSCT). The median DOR values of all patients and the patients who did not receive HSCT were not reached. Hence, the VA\u2010CAG regimen is a safe and effective first\u2010line induction chemotherapy for ND\u2010AML patients.\n                  <\/jats:p>","DOI":"10.1002\/hem3.70449","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:58:33Z","timestamp":1786460313000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax plus azacitidine, low\u2010dose cytarabine, aclarubicin, and G\u2010CSF (VA\u2010CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single\u2010arm Phase II clinical trial"],"prefix":"10.1002","volume":"10","author":[{"given":"Xiaoping","family":"Li","sequence":"first","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiurong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Haematology The First Affiliated Hospital of Dali University Dali China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Haematology The People's Hospital of Baoshan Baoshan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglin","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology The Southern Central Hospital of Yunnan province Gejiu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Haematology The People's Hospital of Chuxiong Chongxiong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Haematology The Northeast Yunnan Center Hospital Zhaotong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtao","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqian","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Haematology The People's Hospital of Yuxi City Yuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqiong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology The People's Hospital of Lijiang Lijiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyuan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Haematology Xishuangbanna Dai Autonomous Prefecture People's Hospital Jinghong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zucong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Haematology The People's Hospital of Dehong Prefecture Mangshi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxiu","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Haematology Dali Bai Autonomous Prefectue People's Hospital Dali China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Haematology The Second People's Hospital of Qujing Qujing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renpeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Haematology The First People's Hospital of Zhaotong Zhaotong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology The People's Hospital of Lincang Lincang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yancheng","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingsong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aifang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Haematology The People's Hospital of Baoshan Baoshan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology The Southern Central Hospital of Yunnan province Gejiu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Haematology The Northeast Yunnan Center Hospital Zhaotong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Haematology Qujing Central Hospital of Yunnan Province Qujing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Haematology Qujing Central Hospital of Yunnan Province Qujing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoen","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Haematology and Rheumatism Immunity The People's Hospital of Puer Puer China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4226-9580","authenticated-orcid":false,"given":"Yang","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hematological Oncology, State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat\u2010sen University Cancer Center Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3871-5114","authenticated-orcid":false,"given":"Sanbin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Cancer Statistics Explorer Network"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.38.5.5249"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1885663"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2017.52.3.174"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0842"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1578152"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164238"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.08.010"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27434"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1714"},{"key":"e_1_2_11_13_1","first-page":"2768","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first\u2010line treatment for adults with acute myeloid leukaemia: a multicentre, single\u2010arm, phase 2 trial","volume":"39","author":"Wang H","year":"2022","journal-title":"Lancet Haematol"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00192-7"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03736"},{"key":"e_1_2_11_16_1","first-page":"10","article-title":"Concurrent use of granulocyte colony\u2010stimulating factor with low dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study","volume":"9","author":"Yamada K","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-4-46"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1443328"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102973"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027217"},{"key":"e_1_2_11_22_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Cancer Institute.2020. Accessed January 12 2022.https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1409302"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0479"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02625-3"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25567"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2211429119"},{"key":"e_1_2_11_28_1","first-page":"3051","article-title":"The t(8;21) translocation is not consistently associated with high Bcl\u20102 expression in de novo acute myeloid leukemias of adults","volume":"4","author":"Banker DE","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00034-6"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02823"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70449","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:02:19Z","timestamp":1788033739000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/hem3.70449"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70449","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2025-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70449"}}